Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | GUCY1A1 | Q02108 | 9/20 | 0.54 |
| ▸ | GUCY1B1 | Q02153 | 9/20 | 0.54 |
| ▸ | PDE5A | O76074 | 9/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19399351 | 0.88 | ADORA3 (0.57) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL21227075 | 0.86 | ADORA3 (0.65) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL174771 | 0.86 | ADORA3 (0.66) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL15015881 | 0.86 | ADORA3 (0.66) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL27557122 | 0.85 | ADORA3 (0.67) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Riociguat SCHEMBL245457 | 0.84 | KCNH2 (1.00) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Riociguat SCHEMBL29357210 | 0.84 | KCNH2 (1.00) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Riociguat SCHEMBL29379983 | 0.84 | KCNH2 (1.00) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| Riociguat SCHEMBL29419573 | 0.84 | KCNH2 (1.00) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL29379641 | 0.84 | ADORA3 (0.73) | ADORA3KCNH2GUCY1A1GUCY1B1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11357777-B2 | Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH) | CYCLERION THERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11357777-B2 | Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH) | GLS2, GPR119, PRKG1 | ADORA3 2184/4885KCNH2 4187/4885GUCY1A1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.